Table 1 Clinical and Baseline characteristics
From: Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia
Characteristics | All Patients (%) | ZHX 1 | p | ZHX2 | p | ||
|---|---|---|---|---|---|---|---|
Low | High | Low | High | ||||
Age, y Median (range) | 65 (43, 85) | 65.5 (54, 80) | 59 (43, 85) | .44 | 66.5 (54, 80) | 59 (43, 85) | .15 |
Sex | .24 | .01 | |||||
Female | 21 (41.1) | 9 (34.6) | 12 (48) | 5 (20.8) | 13 (56.5) | ||
Male | 30 (58.9) | 17 (65.4) | 13 (52) | 19 (79.2) | 10 (43.5) | ||
Binet | .26 | .60 | |||||
A | 35 (68.7) | 17 (68) | 18 (69.2) | 16 (48.5) | 17 (51.5) | ||
B | 11 (21.5) | 4 (16) | 7 (27) | 5 (50) | 5 (50) | ||
C | 5 (9.8) | 4 (16) | 1 (3.8) | 3 (75) | 1 (25) | ||
Platelets | .16 | .55 | |||||
median (range), X109 /L | 142.5 (11, 312) | 137.5 (15, 261) | 147 (11, 312) | 141.5 (15, 312) | 140 (11, 284) | ||
WBC | .03 | .15 | |||||
median (range), X109 /L | 45.2 (7.8, 170.1) | 61.1 (29, 170.1) | 23.4 (7.8, 93.2) | 45.3 (10.5, 170.1) | 30.1 (7.8, 93.2) | ||
ZAP-70a | .18 | .37 | |||||
Negative | 16 (32) | 6 (24) | 10 (40) | 7 (30.4) | 9 (39.1) | ||
Positive | 34 (68) | 19 (76) | 15 (60) | 16 (69.6) | 14 (60.9) | ||
Karyotype | .007 | .04 | |||||
Normal | 12 (23.5) | 2 (7.7) | 10 (40) | 3 (12.5) | 9 (39.1) | ||
Abnormal | 39 (76.5) | 24 (92.3) | 15 (50) | 21 (87.5) | 14 (60.1) | ||
Cytogenetic risk | .002 | .09 | |||||
Favorable | 14 (27.5) | 2 (7.7) | 12 (48) | 4 (16.7) | 10 (43.5) | ||
Intermediate | 20 (39.2) | 11 (42.3) | 9 (36) | 11 (45.8) | 9 (39.1) | ||
Adverse | 17 (33.3) | 13 (50) | 4 (16) | 9 (37.5) | 4 (17.4) | ||
Number of karyotypic changes | .003 | .01 | |||||
0 | 12 | 2 (7.7) | 10 (40) | 3 (12.5) | 9 (39.1) | ||
1 or 2 | 26 | 13 (50) | 13 (52) | 13 (54.2) | 13 (56.5) | ||
3 or more | 13 | 11 (42.3) | 2 (8) | 8 (33.3) | 1 (4.4) | ||